Pemvidutide: A Tracking Guide for a GLP-1 and Glucagon Agonist

Pemvidutide is an investigational peptide with balanced, roughly 1:1 glucagon and GLP-1 dual receptor agonist activity, developed by Altimmune. The GLP-1 arm suppresses appetite and drives weight loss, while the glucagon arm acts directly on the liver to cut liver fat, inflammation, and fibrosis. It is notable in its class for lean-mass sparing: in the MOMENTUM Phase 2 obesity trial, body composition analysis attributed about 78 percent of weight lost to fat and 22 percent to lean mass, and its IMPACT Phase 2b program showed significant MASH resolution.

Pemvidutide is investigational and not approved; a Phase 3 MASH trial (PERFORMA) was planned for 2026. This is an educational tracking guide, not medical advice or a recommendation.

What it does

• Combines GLP-1 appetite suppression with direct glucagon effects on the liver
• Drives fat loss with comparatively strong lean-mass preservation
• Reduces liver fat, triglycerides, LDL, and blood pressure in trials, and showed MASH resolution

Typical protocol shape

In the trials, pemvidutide is titrated upward over weeks to a maintenance dose to limit GI effects, given once weekly by subcutaneous injection. Doses referenced anywhere are trial context only, not a recommendation.

What to track daily

• Appetite, portion sizes, and fullness
• Nausea, vomiting, diarrhea, or constipation
• Resting heart rate

What to track weekly

• Bodyweight under consistent conditions
• Waist circumference
• Injection-site tolerance
• Grip strength or a simple lift; the lean-mass sparing profile is a reason to track muscle carefully to confirm it in your own case

Bloodwork worth doing

• Liver enzymes and, where relevant, fibrosis markers, given the MASH focus
• Fasting glucose and HbA1c
• Lipid panel and blood pressure over time

Realistic expectations

The lean-mass sparing story is a trial-level average, not a guarantee for any individual, so muscle tracking still matters. Weight and liver benefits build over months. Protein and resistance training remain worthwhile even with a lean-sparing agent.

Common mistakes

• Assuming lean-mass sparing means muscle work is unnecessary
• Treating an investigational drug as characterized and available
• Ignoring GI intolerance during titration

Safety notes

Pemvidutide is investigational and not approved. Its full safety profile is still being defined, and glucagon agonism adds metabolic and heart-rate considerations on top of GLP-1 class GI effects. Any non-trial access is outside the evidence base; use only with medical supervision.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.